Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections

NCT06939829 is registered in ClinicalTrials.gov with Southeast University, China as lead sponsor.

NCT NCT06939829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06939829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
Lead sponsor
Southeast University, China
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
December 31, 2027
Enrollment
1,200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with critically ill infections